ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors
暂无分享,去创建一个
[1] I. Steffen,et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours , 2012, European Radiology.
[2] S. Libutti,et al. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. , 2011, Surgery.
[3] C. Boy,et al. 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.
[4] P. Cumming,et al. Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.
[5] F. Lv,et al. Laparoscopic ultrasound enhances diagnosis and localization of insulinoma in pancreatic head and neck for laparoscopic surgery with satisfactory postsurgical outcomes. , 2011, Ultrasound in medicine & biology.
[6] V. Ambrosini,et al. Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT , 2011, The Journal of Nuclear Medicine.
[7] H. Amthauer,et al. 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.
[8] Yi Wang,et al. Diffusion‐weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics , 2011, Journal of magnetic resonance imaging : JMRI.
[9] J. Buckels,et al. Preoperative Localisation and Surgical Management of Insulinoma: Single Centre Experience , 2011, Digestive Surgery.
[10] P. Veit-Haibach,et al. Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component , 2011, European Radiology.
[11] A. Bockisch,et al. The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors , 2010, Annals of surgery.
[12] T. Baère,et al. Endocrine pancreatic tumours: which are the most useful MRI sequences? , 2010, European Radiology.
[13] I. Kayani,et al. The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.
[14] J. Mortensen,et al. Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET , 2010, Journal of Nuclear Medicine.
[15] M. Bergström,et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. , 2010, Nuclear medicine and biology.
[16] Ka Kit Wong,et al. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. , 2010, Academic radiology.
[17] E. Baudin,et al. Hepatic Metastases From Neuroendocrine Tumors With a “Thin Slice” Pathological Examination: They are Many More Than You Think … , 2010, Annals of surgery.
[18] I. Virgolini,et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[19] V. Ambrosini,et al. 68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[20] A. Kjaer,et al. F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .
[21] E. D. de Vries,et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. , 2009, Critical reviews in oncology/hematology.
[22] David Gross,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers , 2009, Neuroendocrinology.
[23] M. Falconi,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.
[24] E. Krenning,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs , 2009, Neuroendocrinology.
[25] R. Bale,et al. Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009, Journal of Nuclear Medicine.
[26] E. Krenning,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide , 2009, Neuroendocrinology.
[27] Pierre Bedossa,et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. , 2009, Radiology.
[28] G. Kaltsas,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.
[29] J. Walecki,et al. Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs , 2008, Journal of Nuclear Medicine.
[30] P. Erba,et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[31] A. Groves,et al. A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors , 2008, Journal of Nuclear Medicine.
[32] V. Ambrosini,et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[33] A. Kjaer,et al. Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors , 2008, Neuroendocrinology.
[34] V. Deshpande,et al. Improved Contemporary Surgical Management of Insulinomas: A 25-year Experience at the Massachusetts General Hospital , 2008, Annals of surgery.
[35] F. Zeinali,et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma , 2007, Endocrine.
[36] R. Bale,et al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.
[37] M. Zahiah,et al. Intraoperative Ultrasound with Palpation is Still Superior to Intra-arterial Calcium Stimulation Test in Localising Insulinoma , 2007, World Journal of Surgery.
[38] A. Ignee,et al. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography , 2007, Scandinavian journal of gastroenterology.
[39] J. Saurin,et al. Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. , 2006, Radiology.
[40] S. Choi,et al. LOCALIZATION AND SURGICAL TREATMENT OF THE PANCREATIC INSULINOMAS , 2006, ANZ journal of surgery.
[41] E. D. de Vries,et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.
[42] Wei Yang,et al. The role of contrast-enhanced sonography of focal liver lesions before percutaneous biopsy. , 2006, AJR. American journal of roentgenology.
[43] A. Hubalewska-Dydejczyk,et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[44] H. Lochs,et al. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. , 2006, Gastrointestinal endoscopy.
[45] V. Vilgrain,et al. Endocrine Pancreatic Tumours and Helical CT: Contrast Enhancement Is Correlated with Microvascular Density, Histoprognostic Factors and Survival , 2006, Pancreatology.
[46] S. Libutti,et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. , 2005, Surgery.
[47] Filippo Cademartiri,et al. Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US , 2005, European Radiology.
[48] A. Harris,et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.
[49] A. Ferrari,et al. EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. , 2004, Gastrointestinal endoscopy.
[50] A. Ba-Ssalamah,et al. The importance of preoperative localisation procedures in organic hyperinsulinism — Experience in 67 patients , 2004, Wiener Klinische Wochenschrift.
[51] R. Wahl,et al. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS , 2004, Abdominal Imaging.
[52] H. Gouya,et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. , 2003, AJR. American journal of roentgenology.
[53] M. Kanematsu,et al. Spectrum of MRI appearances of untreated metastases of the liver. , 2003, AJR. American journal of roentgenology.
[54] J. Fletcher,et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. , 2003, AJR. American journal of roentgenology.
[55] J. Norton,et al. Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6. , 2001, Archives of surgery.
[56] M. Falconi,et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization , 2001, European Radiology.
[57] Michelle A. Anderson,et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.
[58] T. Ichikawa,et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. , 2000, Radiology.
[59] B. Wiedenmann,et al. Endoscopic Ultrasonography of Neuroendocrine Tumours , 2000, Digestion.
[60] A. Ferrari,et al. Role of EUS in the preoperative localization of insulinomas compared with spiral CT. , 2000, Gastrointestinal endoscopy.
[61] U. Mueller-Lisse,et al. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. , 2000, Radiology.
[62] C. Angelis,et al. Endosonography in decision making and management of gastrointestinal endocrine tumors. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.
[63] J. Doppman,et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[64] D. Huglo,et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. , 1998, Surgery.
[65] S. Fanti,et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours , 1998, European Journal of Nuclear Medicine.
[66] J. Laissue,et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. , 1997, The Yale journal of biology and medicine.
[67] S. Sironi,et al. Value of abdominal sonography and MR imaging at 0.5 T in preoperative detection of pancreatic insulinoma: a comparison with dynamic CT and angiography , 1997, Abdominal Imaging.
[68] J. Doppman,et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. , 1997, Gastroenterology.
[69] H. Buhr,et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. , 1996, Gut.
[70] Y. Chapuis,et al. Endoscopic Ultrasonography for the Preoperative Localization of Insulinomas , 1996, Pancreas.
[71] T. Frieling,et al. Prospective study on the detection of insulinomas by endoscopic ultrasonography. , 1996, Endoscopy.
[72] P. Ruszniewski,et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. , 1995, Surgery.
[73] E. Krenning,et al. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. , 1994, European journal of pharmacology.
[74] B. Wiedenmann,et al. Localisation of neuroendocrine tumours of the upper gastrointestinal tract. , 1994, Gut.
[75] J. Laissue,et al. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. , 1992, Gastroenterology.
[76] C. Lightdale,et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.
[77] W. Lees,et al. Endoscopic ultrasound for localisation of islet cell tumours. , 1992, Gut.
[78] E. Goetzl,et al. Distinct subsets of somatostatin receptors on cultured human lymphocytes. , 1989, The Journal of biological chemistry.
[79] B Gorman,et al. Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. , 1988, Radiology.
[80] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[81] R. Bale,et al. Tyr 3 -Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009 .
[82] C. Nanni,et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[83] T. de Baère,et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] T. de Baère,et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. , 2003, AJR. American journal of roentgenology.
[85] J. Laissue,et al. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.
[86] J. Valentin,et al. Radiation dose to patients from radiopharmaceuticals , 1998 .
[87] J. Mcnamara,et al. Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. , 1998, American journal of surgery.
[88] J C Reubi,et al. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.